晚期青光眼治疗研究中视野与生活质量纵向变化
这项多中心随机临床试验纳入453例新诊断晚期开角型青光眼成人患者,比较小梁切除术与药物治疗作为初始治疗对视野和生活质量5年变化的影响。结果显示小梁切除术组指标眼视野损失速率更慢,但双眼整合视野下降和生活质量变化组间无统计学差异,视野与生活质量相关性在双眼整合视野上更强。
要点
- 小梁切除术组指标眼视野损失速率较药物治疗组更慢。
- 双眼整合视野下降和生活质量变化组间无统计学差异。
- 双眼整合视野与生活质量的相关性强于单眼指标眼视野。
核心结论
- 在小梁切除术与药物治疗晚期青光眼的比较中,小梁切除术更有效地减缓了指标眼视野损失速率。
- 尽管双眼整合视野与生活质量存在中等强度相关性,但未发现组间生活质量测量差异,提示VFQ-25可能对单眼青光眼干预不够敏感。
研究设计与样本
- 多中心随机临床试验,在英国27个二级照护青光眼科开展。
- 纳入453例新诊断晚期开角型青光眼成人,随机分为小梁切除术组(n=227)或药物治疗组(n=226)作为初始治疗,每人确定一只合格指标眼。
- 主要结局为5年单眼指标眼视野、双眼整合视野和VFQ-25综合评分的变化速率组间平均差异,采用贝叶斯纵向分层模型意向性分析。
- 分析纳入442例有可靠视野(假阳性率≤15%)或VFQ-25数据超过2个时间点的患者,其中小梁切除术优先组221例。
主要发现
- 药物治疗优先组指标眼视野损失速率为-0.75 dB/年(95% CrI,-0.90至-0.59),小梁切除术优先组为-0.37 dB/年(95% CrI,-0.53至-0.22),P=0.002。
- 双眼整合视野下降组间差异无统计学意义(P=0.062)。
- VFQ-25变化组间差异无统计学意义(P=0.392)。
- 双眼整合视野与生活质量的相关性在基线为0.41(95% CrI,0.32-0.49;P<0.001),变化速率为0.56(95% CrI,0.41-0.70;P<0.001)。
- 指标眼视野与生活质量的相关性在基线为0.22(95% CrI,0.12-0.32;P<0.001),变化速率为0.43(95% CrI,0.26-0.58;P<0.001)。
关键数值与推荐
- 指标眼视野损失速率组间差异P=0.002。
- 双眼整合视野下降组间差异P=0.062。
- VFQ-25变化组间差异P=0.392。
- 双眼整合视野与生活质量基线相关性0.41(95% CrI,0.32-0.49;P<0.001),变化速率相关性0.56(95% CrI,0.41-0.70;P<0.001)。
- 指标眼视野与生活质量基线相关性0.22(95% CrI,0.12-0.32;P<0.001),变化速率相关性0.43(95% CrI,0.26-0.58;P<0.001)。
临床怎么用
- 对于新诊断晚期开角型青光眼,小梁切除术作为初始治疗可能更有效减缓单眼视野损失速率。
- VFQ-25可能不足以反映单眼青光眼干预带来的生活质量变化,临床评估生活质量时需考虑其敏感性局限。
- 双眼整合视野与生活质量相关性更强,或可作为更贴近患者感受的视野评估指标。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Progressive visual field (VF) loss resulting from glaucoma affects quality of life (QoL). Although treatments aim to preserve vision, the extent to which slowing VF loss translates into QoL changes in advanced disease is not understood fully. We compare the 5-year rate of VF and QoL change and examined their correlation in the Treatment for Advanced Glaucoma Study. DESIGN: Multicenter randomized clinical trial (27 secondary care glaucoma departments in the UK). PARTICIPANTS: Adults (n = 453) with newly diagnosed advanced open-angle glaucoma in at least 1 eye were randomized to trabeculectomy (n = 227) or medical management (n = 226) as initial treatment. One eligible index eye was identified per participant. MAIN OUTCOME MEASURES: Mean difference in rate of change in monocular index eye VF (24-2 SITA Standard), binocular integrated (BI) VF, and the 25-item Visual Function Questionnaire (VFQ-25) composite score over 5 years (intention to treat) using a Bayesian longitudinal hierarchical model. RESULTS: Data from 442 patients with reliable VF (false-positive rate ≤15%) or VFQ-25 data from >2 time points were included (221 patients in the trabeculectomy-first arm). Baseline characteristics were similar between arms. The rate of index eye VF loss was faster in the medications-first arm (-0.75 [95% credible interval (CrI), -0.90 to -0.59] dB/year) compared with the trabeculectomy-first arm (-0.37 [95% CrI, -0.53 to -0.22] dB/year; P = 0.002). Differences between groups were not statistically significant for BI VF decline (P = 0.062) or VFQ-25 change (P = 0.392). Correlations between VF and QoL were stronger for BI VF for baseline (0.41 [95% CrI, 0.32-0.49]; P < 0.001) and rate of change (0.56 [95% CrI, 0.41-0.70]; P < 0.001) than for index eye VF (0.22 [95% CrI, 0.12-0.32]; P < 0.001 and 0.43 [95% CrI, 0.26-0.58]; P < 0.001, respectively). CONCLUSIONS: Trabeculectomy more effectively reduced the rate of VF loss compared with medical treatment in advanced glaucoma. Despite a moderately strong correlation with the BI VF, no difference was found in the measured QoL, suggesting that the VFQ-25 might not be reactive or sensitive enough to monocular glaucoma interventions. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Montesano G, Ometto G, Cheloni R, et al. Longitudinal Visual Field and Quality-of-Life Change in the Treatment for Advanced Glaucoma Study. Ophthalmology. 2026. PMID: 42036075. doi:10.1016/j.ophtha.2026.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。